Starting a clinical trial in itself is never really much of an event once approval has been granted it's really just the expected progression. It will possibly build value towards the expected completion of the trial sometime over the next 3-4months but the real fire starter as always will be the unexpected out of leftfield.
My picks for triggers -
>> "aggressively seeking complementary new opportunities."
>> Up scaled marketing of BNE under the new board & path forward.
>> appointment of new CEO ?
>> BN006 - mechanism of action & update from WHRI potentially pushing into human clinical trials &/or maybe out-license.
>> anything else out of leftfield
trial commencement, page-9
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |